/

FSNUY

Fresenius SE & Co. KGaAOpen

12.42+0.43 +3.59%USD

OTC Markets OTCPK · as of Oct 14, 15:22 ET · 15m delay

Open

12.20

Prev close

11.99

Day range

12.1912.49

52-week range

10.3333.93

Volume

111.75K0.53×

Mkt cap

27.98B

P/E ttm

15.33

Fwd P/E

4.30

EPS ttm

0.8100

Div yield

2.52%

Earnings

—

From 52w high

−63.40%

Price Chart

Yahoo Finance · delayed

FSNUYOct 14, 2026O 12.20H 12.49L 12.19C 12.42+0.34 (+2.81%)Vol 111.75K

SMA 5013.08
SMA 20012.94

1Y change −10.65% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

FSNUY Fresenius SE & Co. KGaA · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +1.89%
1 month: −6.05%
3 months: +3.41%
6 months: −4.75%
Year to date: −13.33%
1 year: −12.41%

Valuation & ownership

Market cap: 27.98B
Enterprise value: 38.06B
P/E (ttm): 15.33
Forward P/E: 4.30
PEG ratio: 0.76
Price / book: 1.27
Price / sales (ttm): 1.20
EV / EBITDA: 12.52
EPS (ttm): 0.8100
EPS (forward): 2.89
Beta (5y monthly): 0.82
Dividend yield: 2.52%
Payout ratio: 37.73%
Shares outstanding: 2.25B
Float: 1.64B
Short % of float: —
Short ratio (days): —
Held by insiders: 0.00%
Held by institutions: 0.00%
Avg volume (3m): 212.81K
50-day average: 13.09
200-day average: 12.95
52-week change: −12.41%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 45.2
vs 50-day SMA: −5.05%
vs 200-day SMA: −4.04%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 3.54%
Realised vol (20d, ann.): 31.0%
From 52-week high: −63.40%
From 52-week low: +20.23%

ANR

Analyst Consensus

3 analysts

Consensus

Strong buy

1.33 on a 1 (strong buy) – 5 (sell) scale

Mean target

16.11

+29.71% implied

Low 14.13Median 15.90High 18.30

Recommendation trend

Now3 / 0 / 0
1m ago3 / 0 / 0

DES

About Fresenius SE & Co. KGaA

Yahoo Finance profile

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

Sector: Healthcare
Industry: Medical Care Facilities
Employees: 178,486
Headquarters: Bad Homburg vor der Höhe, Germany
Website: fresenius.com
Officers: Mr. Michael Sen CEO, President & Chairman of Management Board of Fresenius Management SE

SEAS

Seasonality · FSNUY

2012–2026 · monthly returns

Strongest month Apr +4.05%Weakest month Feb −2.16%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-2.4	7.9	-14.8	-4.9	-13.1	7.4	12.7	2.4	-4.0	-1.9			−13.3%
2025	9.7	4.2	7.9	10.4	3.4	1.5	-4.4	14.2	2.9	59.8	-38.8	4.4	+63.8%
2024	-9.6	-0.4	-2.7	11.5	5.3	-5.4	20.1	3.0	3.0	-4.3	-3.5	-1.1	+13.2%
2023	2.9	-5.1	-1.9	7.0	-4.2	1.3	12.4	2.8	-2.7	-18.3	24.6	-2.8	+10.6%
2022	5.4	-17.4	7.0	-4.6	-3.4	-12.3	-14.2	-3.3	-13.9	6.0	21.6	1.0	−30.0%
2021	-4.4	-3.4	3.9	11.0	10.4	-4.2	1.9	-2.5	-8.3	-4.3	-17.6	5.8	−14.3%
2020	-8.5	-8.4	-21.5	18.0	11.9	2.5	-0.3	-7.2	-0.9	-18.7	20.4	4.4	−16.5%
2019	6.7	8.8	-0.6	1.9	-11.1	6.1	-8.0	-2.5	-3.9	13.0	3.9	2.3	+14.9%
2018	13.0	-7.0	-6.0	-0.9	1.1	4.4	-3.8	-1.0	-4.3	-13.0	-10.8	-14.4	−37.5%
2017	1.2	0.7	1.2	1.1	6.0	0.3	-1.9	0.3	-4.5	3.9	-14.3	7.7	−0.3%
2016	-7.3	0.7	9.4	0.0	3.7	-3.1	1.7	-2.3	9.7	-7.5	-3.3	9.1	+9.1%
2015	10.4	0.0	3.9	0.2	6.9	1.1	7.4	2.8	-5.6	9.6	-0.3	-2.8	+37.6%
2014	1.0	-1.1	1.6	-3.7	-1.1	0.0	-0.4	-2.0	1.7	3.7	5.4	-4.3	+0.5%
2013	6.4	0.3	0.8	0.7	-5.4	4.5	1.7	-4.6	4.1	4.0	8.7	9.8	+34.4%
2012						10.9	3.8	-0.7	8.4	-2.7	3.5	0.3	+25.1%

CONG

Congress Trades · FSNUY

House and Senate reports since 2025

Members

1 last bought

Buys

~$8.0K

Sells

~$0

Net

+$8.0K

est. bought − sold

Latest

Mar 30, 26

Alan Armstrong

Members who traded it

Member	Buys	Sells	Est. net	Last move
Alan Armstrong Sen. OK	1		+$8.0K	Bought Mar 30, 26

Bought and sold by quarter (est.)

Members of Congress's FSNUY trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Mar 30, 26	Alan Armstrong Sen. OK	Self	Buy	$1,001 - $15,000	Jul 21, 26 (113d)	Report

From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

FSNUY

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

FSNUY

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Fresenius SE & Co. KGaA

Seasonality · FSNUY

Insider Activity · FSNUY

Congress Trades · FSNUY

Members who traded it

Bought and sold by quarter (est.)

Investors Holding FSNUY

Investors Holding FSNUY

Congress Trades · FSNUY

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · FSNUY

Seasonality · FSNUY

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Fresenius SE & Co. KGaA

Financial Snapshot

Earnings & Dividends

News